Harald Schnidar

Harald Schnidar is the CEO, President, and Founder of SCARLETRED. Harald has over fifteen years of experience in the biologics and pharmaceutical industry. Prior to founding SCARLETRED, they were a Business Associate at APEIRON Biologics and Project Head for the clinical development of liposomal enclosed recombinant human Superoxide Dismutase (APN201). Before that, they were a Post Doctoral Research Assistant at Universität Salzburg where they worked on identifying tumor biomarkers in Multiple Myeloma cancer stem cells and on adipogenesis. Harald has also been a PhD. Project Employee in Science and a Scientific Project Employee at Universität Salzburg.

Harald Schnidar has a Mag.rer.nat. from Universität Salzburg in genetics, an MBA from the University of Westminster in business, management, and marketing, an MBA from the University of Toronto - Rotman School of Management in international economy, and an international executive MBA from SMBS - University of Salzburg Business School in economics. Harald also has a master's degree in business administration from Universität St. Gallen-Hochschule für Wirtschafts-, Rechts- und Sozialwissenschaften in business management and a PhD in molecular genetics from Universität Salzburg.

Some direct reports include Kathrin Schnidar - CFO, Stefan Schnidar - CTO.